A new drug for multiple sclerosis, with anti-inflammatory and immunomodulatory effects, has been shown in two clinical trials, whose results have been published in the prestigious 'The New England Journal of Medicine', which is able to reduce the rate of outbreaks by 50% characteristic of this disease.
At present, multiple sclerosis has no cure, and the therapies that are administered to patients aim to stop the progression of the disease and alleviate the symptoms and complications that may occur. Therefore, any new breakthrough in the treatment of multiple sclerosis is a great hope for all people affected by this disease, which is considered the main cause of neurological disability in young adults.
The new drug is able to reduce the rate of multiple sclerosis outbreaks by 50%
In the studies carried out to verify the effectiveness of the new drug - known as 'Define and' Confirm -, the researchers observed that not only is it able to reduce the number of outbreaks, but it also decreases the appearance between 71 and 99 percent. of new brain injuries. In addition, in the patients who participated in the 'Define' study, the progression of the disability that causes the disease was also reduced by 38%.
The new drug, called BG-12, it was administered to patients in doses of 240 mg, two or three times a day, and its side effects-diarrhea and other intestinal disorders, as well as facial flushing-are infrequent and well tolerated by those affected.
The drug most used to control the disease is interferon, whose safety is demonstrated. However, it is not effective in all cases, and some patients continue to have outbreaks, so it is sometimes necessary to resort to other substances, which can have serious side effects. For this reason, if BG-12 is finally approved for its use, it could become the drug of first choice-both for its efficacy and for its convenient administration-in the treatment of multiple sclerosis.